Image Credit: Freepik
Timothy had always been health-conscious. After years of social drinking, she decided to quit alcohol for good. But giving up the ritual of sipping on a drink at social gatherings felt impossible. That's when alcohol-free beer and wine seemed like the perfect alternative—offering the taste and experience without the intoxication. However, what Sarah didn't realize was that these supposedly "harmless" drinks might still be affecting her liver in ways she hadn't anticipated.
With a global shift toward healthier choices, the rise of alcohol-free beverages has been fuelled. Do these drinks, however, live up to their promise of being risk-free? New research shows that while they may eliminate the dangers of intoxication, they still pose metabolic and liver-related risks, which calls for moderation in the long run.
The first time you take a sip of an alcohol-free beverage, your body responds almost instantly. Anshul Singh, Lead Clinical Nutritionist and Dietetics Department says, "In as little as 10 minutes, your taste buds have picked up on the flavors, and your brain might even get a placebo effect, giving you the sensation that you're about to be drunk. Some alcohol-free drinks have up to 0.5% ABV, which goes into the bloodstream in minute quantities but will probably not affect you in any significant way."
By the 30-minute mark, your body has metabolized the sugars, artificial sweeteners, or additives in the drink. "Some people may experience a mild insulin spike, which can cause temporary energy boosts. Some non-alcoholic drinks also contain fermentation byproducts or botanical extracts that mimic the sedative effects of alcohol, causing slight drowsiness or relaxation," adds Anshul.
After 60 minutes, most of the drink has been metabolized. Although there is no risk of intoxication, repeated consumption can subtly affect metabolism, gut health, and even trigger cravings for alcohol among those in recovery. Those sensitive to sugar, caffeine, or preservatives might experience even more pronounced effects over time.
Your liver and gut health are connected, forming what is called the gut-liver axis. Anshul emphasises, "Even though drinks without alcohol seem harmless, they usually contain sugars, artificial sweeteners, and fermentation byproducts that can disturb this delicate balance."
Long-term consumption of these drinks may gradually affect digestion, liver detoxification, and overall metabolic health, making moderation necessary.
Even though these nonalcoholic beverages contain virtually insignificant alcohol, the liver processes them as well. "These small concentrations of alcohol-which may go as high as 0.5% ABV-trigger the liver's detoxification pathways but only at much weaker intensities compared to ordinary alcoholic drinks. But the added sugars, artificial sweeteners, and preservatives in the products could pose significant pressure on liver functions over the long term," explains Anshul.
High sugar intake causes insulin resistance, which can lead to the buildup of fat in the liver and increase the risk of developing NAFLD. Some fermentation byproducts in these beverages also trigger oxidative stress, which puts extra pressure on the liver. Though occasional consumption will not pose a significant threat, regular consumption might lead to chronic liver stress and metabolic imbalance.
Although trace amounts of alcohol exist in alcohol-free beer and wine, the body will still have to metabolize them. The body employs the same enzymatic pathways used for alcoholic beverages but at a much lower intensity. However, the added sugars, preservatives, and fermentation byproducts present their own set of challenges:
Alcohol-free drinks do not cause the liver to become overwhelmed as traditional alcohol does, although it does have a lower, but still important, risk for someone who is drinking too much. For someone with a problem of liver disease or metabolic syndrome, limiting alcohol-free drinks is also important.
Alcoholic beverages have always been a dangerous drink, but the safer option for those who want to avoid intoxication. However, it is not totally risk-free. Its impact on metabolism, gut health, and liver function cannot be ignored. Although they are not harmful at first, their consumption over a long period leads to insulin resistance, liver stress, and imbalance in the gut.
For the consumers who love these drinks, moderation is the way forward. The expert shares, "The choice of brands with the least additives, lower sugar, and natural ingredients will reduce risks. In addition, supplementing with a diet that is rich in antioxidants, fiber, and hydration can complement the liver in general."
For most, thought that adopting alcohol-free beverages was a healthier decision. On discovering their side effects on liver health, though, she learned to limit its intake and settle for alternatives that included infused sparkling water, herbal teas, or even kombucha with controlled sugar levels.
The bottom line? Alcohol-free doesn't mean consequence-free. The best way to achieve long-term health is by paying attention to what goes into the body and yet still enjoy social rituals of preference.
Anshul Singh is the Team Lead with the Clinical Nutrition and Dietetics Department at Artemis Hospitals in India.
Credit: iStock
When patients first hear the term "bone marrow transplant," they often picture a complex surgery involving the bones or spine. This is perhaps the most persistent misconception surrounding one of modern medicine's most remarkable achievements.
Unlike other organ transplants (kidney/ heart/ liver, etc), a bone marrow transplant is not a surgery at all! It is administered much like a blood transfusion, through a simple intravenous line. Yet this deceptively simple procedure can rebuild an entire blood-forming and immune system from scratch, offering a genuine cure for blood cancers and other serious blood disorders.
Bone marrow is the body's blood factory, producing the red cells that carry oxygen, the white cells that fight infection, and the platelets that prevent bleeding. At its heart lie blood-forming stem cells or the "parent cells" capable of generating every blood cell the body will ever need.
In leukemia and related cancers, these stem cells turn rogue, crowding out healthy ones. In several inherited disorders, the marrow simply fails to manufacture healthy cells at all. A transplant addresses the problem at its root, replacing defective stem cells with healthy ones.
I often explain this to patients using the language of farming. Before sowing fresh seed, a farmer clears the field of weeds. Similarly, before healthy stem cells can be transplanted, doctors must prepare the marrow through chemotherapy and, in select cases, radiation, a stage called conditioning. Once this was punishingly intensive, limiting transplants to the young and fit. Today, reduced-intensity regimens, which are carefully tailored to suit even the old or frail patients, have extended this option to older adults and those with other health conditions.
The transplant itself is almost anticlimactic in its simplicity: stem cells are infused through an IV, with no incision or operating theatre required. These cells possess a natural ability doctors call "homing": they find their own way into the bone marrow and settle there. Over two to four weeks, they begin producing healthy blood, a process called engraftment.
For decades, the greatest obstacle to transplantation was finding a matched donor. Traditionally, only a fully matched sibling would do, leaving many patients, particularly in a genetically diverse country like India, without options. That has changed decisively. Half-matched family transplants and unrelated donors identified through registries now succeed at rates that rival matched-sibling transplants. Nearly every patient today has a realistic path to a suitable donor.
Technology is reshaping this field further. Gene therapy is opening a new chapter for disorders such as sickle cell disease and thalassemia, correcting a patient's own stem cells in the laboratory rather than relying on a donor, though such therapies remain costly and available only in select countries for now.
Recovery, however, is a marathon, not a sprint. It can take months as the immune system rebuilds, requiring vigilant monitoring for infection and for graft-versus-host disease, in which transplanted immune cells attack the patient's own tissues. Advances in immunosuppressive and targeted therapies have greatly improved our ability to manage this complication, allowing most survivors to gradually return to work, education and family life.
A blood cancer diagnosis remains frightening, but treatment has advanced tremendously in two decades. Bone marrow transplantation is no longer experimental or exceptionally hazardous: it is established, evidence-based, and growing safer and more accessible across India.
Its truest achievement is not simply extending life, but restoring it: another birthday, another child watched growing up, another future reclaimed. For these patients, a transplant is quite literally a chance to begin again.
(Dr. Narendra Agrawal, Hematologist and Bone Marrow Transplant Physician and Senior Consultant and Unit Head of Haemato-Oncology at Rajiv Gandhi Cancer Institute & Research Centre.)
Credit: iStock
A six-in-one (hexavalent) vaccine could make India's Universal Immunization Program more efficient, convenient for families, and cost-effective if it becomes widely available at an affordable price, according to a study led by the Ministry of Health and Family Welfare.
The study found that while the hexavalent vaccine has higher upfront procurement costs, it could reduce the number of injections, improve operational efficiency, lower healthcare workload, and save time for caregivers.
The hexavalent vaccine protects children against six diseases with a single injection:
Combining multiple vaccines into one shot reduces the number of injections infants receive during routine immunization visits.
Also read: India Records 20,138 Organ Transplants In 2025; Deceased Donor Transplants Reach 3,526
Researchers found that the vaccine's price is the biggest factor determining the overall cost of introducing it into India's immunization program.
The study estimated that:
The findings were published in the peer-reviewed journal Human Vaccines & Immunotherapeutics.
According to the study, introducing the hexavalent vaccine could:
Read More: India's National Hepatitis Program Screens Over 210.6 Million, Treats 612,000 Patients
India runs one of the world's largest immunization programs, vaccinating nearly 26 million babies every year.
The program protects children against 12 vaccine-preventable diseases, including:
A team of researchers, including from The George Institute for Global Health India, The Gates Foundation, and Gavi, The Vaccine Alliance, assessed two implementation scenarios:
The analysis considered costs from both government and household perspectives, including:
The researchers noted that replacing the current pentavalent, fIPV and DTP booster vaccines with the hexavalent vaccine would initially increase vaccine procurement costs. However, these would be partially offset by savings from:
The team added that based on previous vaccine procurement trends, a 50% reduction in the hexavalent vaccine price would make the switch economically favorable under the primary immunization schedule. Further price reductions could also generate cost savings for the booster-dose scenario.
"Our study demonstrates that although the hexavalent vaccine carries a higher upfront procurement cost, it also generates important efficiencies by reducing injections, easing pressure on frontline health workers, lowering cold-chain requirements and saving caregivers' time. These findings provide important economic evidence that can inform future policy discussions on strengthening India's immunization program," Dr. Susmita said.
Blockbuster GLP-1 drugs, with semaglutide as the key ingredient, have shown promise in treating conditions ranging from diabetes and obesity to certain cancers.
Now, US researchers are set to test whether semaglutide can also help treat alcohol use disorder (AUD), particularly among veterans. AUD affects an estimated 400 million people worldwide, or about 7% of people aged 15 years and older.
The US Department of Veterans Affairs (VA) has announced a new clinical trial to evaluate the effectiveness of semaglutide in treating AUD and is aimed directly at benefiting Veterans.
"By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery," said VA Secretary Doug Collins.
Currently, more than 400,000 US veterans have been diagnosed with AUD, while an estimated 11% of US adults are affected by the condition.
Also read: GLP-1 Weight-Loss Drugs Show Promise for 17 Million With Binge Eating Disorder, Suggests Study
The study, called the Cessation or Reduction of Alcohol Consumption in Veterans (CRACV) trial, will enroll more than 600 veterans across 18 VA medical centers in the US.
Participants aged 18 to 80 with moderate or severe AUD will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety follow-up period.
Researchers will assess changes in alcohol consumption, overall health, and quality of life to determine whether semaglutide could become a new treatment option for alcohol use disorder.
Evidence is also emerging that GLP-1 medications may influence alcohol consumption. A Phase 2 clinical trial published in the American Journal of Psychiatry in July suggests that oral semaglutide may help reduce heavy and harmful drinking, even among people who are not trying to quit alcohol completely.
The trial included 50 adults with moderate to severe alcohol use disorder who wanted to reduce or stop drinking. Participants were randomly assigned to receive either daily oral semaglutide or a placebo for eight weeks.
The semaglutide dose increased from 3 mg per day during the first four weeks to 7 mg per day during the remaining four weeks.
While semaglutide did not significantly reduce laboratory-assessed craving or the average number of drinks per day compared with placebo, it significantly reduced heavy drinking days.
Compared with participants receiving placebo, those taking semaglutide had fewer heavy drinking days during the final four weeks of treatment. They also consumed fewer drinks on drinking days and reported greater reductions in everyday alcohol cravings and alcohol-related negative consequences.
"It could represent a new treatment option for alcohol use disorder, particularly for those who have not benefited from existing medications, and may reduce alcohol-related health and social harms. Importantly, even reducing heavy drinking can lead to meaningful improvements for patients and families," said Joseph Schacht, PhD, professor of psychiatry at the University of Colorado Anschutz School of Medicine.
© 2024 Bennett, Coleman & Company Limited